Nasdaq · CIK 0001505497
BRTX BioRestorative Therapies, Inc.
Insider trading from SEC Form 4. Last filing Oct 20, 2025. Close $1.91 on Oct 9, 2026, +1229% from the 52-week low and -61% from the high.
BioRestorative Therapies, Inc. (BRTX) has 9 SEC Form 4 filings on file from 7 insiders, the latest filed on Oct 20, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at BRTX. The newest: Dale Broadrick (10% owner) sold $1,757 of stock on Oct 28, 2024, filed Nov 5, 2024, scored 12 (weak).
BRTX closed at $1.91 on Oct 9, 2026, 1229% above its 52-week low and 61% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at BioRestorative Therapies, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 12Weak | Dale Broadrick owner sell | $1,757 1,112 shares | -0% | - |
Transactions
Every row filed, 11 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2025 | Lance Alstodt President, CEO, COB | AGrant or award Common Stock | +15,625 | $1.60 | $25k | 187,497 | Oct 20, 2025 |
| Oct 6, 2025 | Francisco Silva VP of Research and Development | AGrant or award Comon Stock | +11,719 | $1.60 | $19k | 171,384 | Oct 20, 2025 |
| Oct 6, 2025 | Lance Alstodt President, CEO, COB | AGrant or award Warrantderivative | +11,719 | $0.00 | $0 | 11,719 | Oct 20, 2025 |
| Oct 6, 2025 | Francisco Silva VP of Research and Development | AGrant or award Warrantderivative | +11,719 | $0.00 | $0 | 11,719 | Oct 20, 2025 |
| Feb 14, 2025 | Nickolay V. Kukekov director | AGrant or award Stock Optionderivative | +52,632 | $0.00 | $0 | 52,632 | Feb 19, 2025 |
| Feb 14, 2025 | Patrick F. Williams director | AGrant or award Stock Optionderivative | +52,632 | $0.00 | $0 | 52,632 | Feb 19, 2025 |
| Feb 14, 2025 | David A Rosa director | AGrant or award Stock Optionderivative | +52,632 | $0.00 | $0 | 52,632 | Feb 19, 2025 |
| Feb 14, 2025 | Robert Eugene Kristal Chief Financial Officer | AGrant or award Stock Optionderivative | +166,492 | $0.00 | $0 | 166,492 | Feb 19, 2025 |
| Feb 14, 2025 | Lance Alstodt President, CEO, COB | AGrant or award Stock Optionderivative | +791,885 | $0.00 | $0 | 791,885 | Feb 19, 2025 |
| Feb 14, 2025 | Francisco Silva VP of Research and Development | AGrant or award Stock Optionderivative | +768,979 | $0.00 | $0 | 768,979 | Feb 19, 2025 |
| Oct 28, 2024 | Dale Broadrick owner | SOpen-market sale Common Stock | -1,112 | $1.58 | $1,757 | 445,933 | Nov 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Lance AlstodtPresident, CEO, COB
- Dale Broadrickowner
- Robert Eugene KristalChief Financial Officer
- Nickolay V. Kukekovdirector
- David A Rosaceo, president, officer, director
- Francisco SilvaVP of Research and Development
- Patrick F. Williamsdirector, cfo, officer
Questions about BRTX
Answered from the filings on this page, as of the latest one.
Are insiders buying BRTX?
No. In the last 90 days no insider at BioRestorative Therapies, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade BRTX on the open market?
Dale Broadrick (10% owner) sold $1,757 of BRTX on Oct 28, 2024 and filed the Form 4 on Nov 5, 2024. InsiderTell scored 12 (weak).
How many insiders file Form 4 at BioRestorative Therapies, Inc.?
7 people have filed a Form 4 at BioRestorative Therapies, Inc., among them Lance Alstodt (President, CEO, COB), Dale Broadrick (10% owner), Robert Eugene Kristal (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.